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Summary 
Bcl-2 expression is tightly regulated during lymphocyte development. Mature lymphocytes in 
Bcl-2-deficient mice show accelerated spontaneous apoptosis in vivo and in vitro. Stimulation 
ofBcl-2-deficient lymphocytes by anti-CD3 antibody inhibited the spontaneous apoptosis not 
only in T  cells but also in B  cells. The rescue of B  cells was dependent on the presence of T 
cells,  mainly through CD40L and interleukin (IL)-4. Furthermore, we generated Bcl-2--defi- 
cient mice transgenic for a T  cell receptor or an immunoglobulin, both specific for chicken 
ovalbumin, to test for antigen-specific T-B cell interaction in the inhibition of the spontaneous 
apoptosis.  The initial T cell activation by antigenic peptides presented by B cells suppressed apop- 
tosis in T  cells. Subsequently, T  cells expressed CD40L and released ILs, leading to the protec- 
tion of  B cells from spontaneous apoptosis. These results suggest that the antiapoptotic signaling 
via CD40 or IL-4 may be largely independent of Bcl-2. Engagement of the Ig alone was not 
sufficient for the inhibition of B cell apoptosis. Thus, the physiological role of Bcl-2 in mature 
lymphocytes may be to protect cells from spontaneous apoptosis and to extend their lifespans to 
increase the opportunity for T cells and B cells to interact with each other and specific antigens 
in secondary lymphoid tissues. Bcl-2, however, appears to be dispensable for survival once ma- 
ture lymphocytes are activated by antigen-specific T-B cell collaboration. 
A 
Poptosis, a type of physiological cell death, is observed 
throughout phylogeny (1). In mammals, apoptosis has 
been  extensively  documented,  particularly  during  lym- 
phoid  and  neuronal  development.  However,  litde  is 
known about the molecular mechanisms that control apop- 
tosis  (2). The product of the bcl-2 protooncogene, a mam- 
malian  homologue  of ced-9  in  Caenorhabditis  elegans, has 
been considered a key negative regulator of apoptosis  (3). 
Deregulated expression of Bcl-2 promotes cell survival by 
preventing apoptosis in many but not all types of cells. For 
example, forced expression of Bcl-2 can inhibit apoptosis 
in  cytokine-dependent cell lines  upon withdrawal  of the 
cytokines (4, 5). However, it has been unclear that Bcl-2 is 
essential for the  signaling  of the  cytokines to  inhibit  cell 
death. 
Endogenous  Bcl-2  is  normally expressed in  long-lived 
cells such as mature lymphocytes and neurons (6, 7). Dur- 
ing lymphocyte development, Bcl-2  expression is  tightly 
regulated.  In  T  cells,  CD4-8-  (double-negative)  thy- 
mocytes express Bcl-2, while Bcl-2 is downregulated at the 
CD4+8 + (double-positive) stage when thymic positive and 
negative selections occur. Bcl-2 is subsequently reexpressed 
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in  CD4+8 -  or CD4-8 +  (single-positive) thymocytes and 
can be further induced upon activation by anti-CD3 mAb 
(8, 9). In B cells, pro-B cells express Bcl-2, whereas Bcl-2 is 
downregulated among pre-B cells and IgM+D -  immature 
B  cells. Thereafter, IgM+D + mature B  cells highly express 
Bcl-2 (10).  In the peripheral lymphoid system, immuniza- 
tion leads  to  the formation of germinal centers in which 
Bcl-2 expression ceases in dividing B cells that undergo so- 
matic hypermutation (6, 11). After selection for high affin- 
ity Ig, Bcl-2 is reexpressed in plasma cells (12) and memory 
B cells (13). Of note, germinal center B cells (Bcl-2-) show 
more spontaneous apoptosis than circulating B  cells  (Bcl- 
2 +)  (14).  The spontaneous apoptosis of germinal center B 
cells can be suppressed by CD40 stimulation.  Since reex- 
pression of Bcl-2 follows the CD40 stimulation, it has been 
suggested that the  upregulation of Bcl-2 may be essential 
for the prevention of apoptosis  caused by CD40  stimula- 
tion. Kinetics studies, however, have suggested that the in- 
duction of Bcl-2 by CD40 stimulation might be secondary 
to the survival signal  through CD40  (15).  Thus,  require- 
ment for Bcl-2 in the survival signal of B cells mediated by 
CD40 has been controversial. 
Abnormalities occurring in bcl-2 gene-disrupted mice are 
consistent with the notion that Bcl-2 is a major regulator of 
the protection from apoptosis in mature lymphocytes. Bcl-2- 
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in  vivo  and  in  vitro,  while  lymphocyte  development  in 
Bcl-2-deficient mice appears intact (16-18).  In a previous 
report, we could not detect any obvious defect in Bcl-2- B 
cell survival in vitro, although the number of B  cells clearly 
decreased in vivo (16, 17). By means of more sensitive assays, 
we could find a  significantly higher degree of apoptosis in 
Bcl-2- mature B  cells in vitro (this report). Preliminary ex- 
periments suggested that stimulation by the anti-CD3 anti- 
body  could  block  T  cell  apoptosis in  Bcl-2-  mice  (16). 
Here, we show that anti-CD3 stimulation inhibited apop- 
tosis, not only in T  cells, but also in B  cells. This effect was 
confirmed by a specific antigen instead of anti-CD3 by us- 
ing Bcl-2-  mice with transgenic TCR  or Ig. This inhibi- 
tion of apoptosis appears to be dependent on cognate T-B 
cell interaction and T  cell activation. In the absence of Bcl-2, 
B  cells present antigenic peptide with  class II MHC  to  T 
cells, resulting in inhibition of T  cell apoptosis and in acti- 
vation, which protects B cells from apoptosis mainly through 
CD40 and lymphokines. Our data suggest that the physio- 
logical role of Bcl-2 in mature lymphocytes appears to be 
the protection of cells from spontaneous apoptosis and the 
extension of their lifespans until they are activated by spe- 
cific antigens. This may be important for increasing the op- 
portunity for T  cells and B  cells to interact with each other 
and specific antigens in secondary lymphoid tissues.  Once 
activated, however, T  and B  cells become more resistant to 
spontaneous apoptosis in a Bcl-2-independent fashion. 
Materials  and Methods 
Animals.  All mice used in this study were maintained in the 
specific pathogen-free animal facility at Washington University. 
Generation of bd-2 gene-disrupted mice was described elsewhere 
(16,  17). Heterozygous mutant mice (bd-2 §  were crossed with 
chicken OVA (cOVA)l-specific TCR transgenic mice (19) or lg 
transgenic mice  (20).  By  intercrossing F1  generation mice,  we 
obtained bcl-2 -/- TCtL or Ig transgenic mice. Similarly, we made 
bd-2 -/-  Ipr  (fas  -/-)  double-mutant mice.  The  mice  that  were 
killed were  2-3-wk old. All experiments were performed with 
littermate control animals. 
Reagents.  All purified and fluorescent dye-conjugated anti- 
bodies in this study were purchased from PharMingen  (San Di- 
ego, CA), except MR-1  (anti-mouse CD40L)  (21), a gift of Dr. 
1 Abbreviations used in this paper: cOVA, chicken OVA; CsA, cyclosporin 
A; EtBr, ethidium bromide. 
tk. j. NoeUe (Dartmouth Medical School, Hanover, NH). I<U- 
486 was a gift of Dr. J. D. Ashwell (National Institutes of Health, 
Bethesda,  MD).  Recombinant mouse  IL-lc~, IL-2, IL-4,  IL-7, 
and  IFN-y were purchased from  Genzyme  Corp.  (Cambridge, 
MA). cOVA protein was purchased from Sigma Immunochemi- 
cals  (St.  Louis, MO).  cOVA protein was  multimerized by glu- 
taraldehyde cross-linking (20). cOVA peptide (323-339) was syn- 
thesized as described (19, 22). 
Cell Culture.  Medium  was  P,,PMI  1640  (GIBCO  BRL, 
Gaithersburg, MD)  with  10%  FCS,  t4 rnM  Hepes  (pH  7.3),  2 
mM  L-glutamine, 0.1  mM MEM  nonessential amino acid solu- 
tion, 0.1 mM sodium pyruvate, 20 U/ml penicillin G, 20 I~g/ml 
streptomycin sulfate, and 25 p,M 2-ME (GIBCO BRL). For most 
cultures, 3 ￿  105 cells were placed in the well of a 96-well v-bot- 
tom plate (Costar Corp., Cambridge, MA) at 37~  CO  2 for 
20 h. For the 72-h cultures, 100 U/ml rlL-4 was added in culture 
for the first 48 h and was removed 24 h before the end of culture. 
In some experiments, subpopulations oflymphocytes were puri- 
fied. For the purification of B cells, adherent cells were removed 
by a brief  spin at 1,000 rpm for 2 rain and after incubation for ] h 
at  37~  CO2.  Nonadherent spleen cells  were  treated with 
anti-Thy-1  antibody  and  complement  lysis.  Viable  cells  were 
harvested by Lympholyte M  gradient separation according to the 
manufacturer's protocol  (Cedarlane Laboratories Ltd.,  Ontario, 
Canada). T  cell lines established from the cOVA-specific TCP, 
transgenic mice were used in some cases (20). 
Flow Cytometry Analysis.  Staining with propidium iodide or 
ethidiurn  bromide  (EtBr;  Sigma)  to  detect apoptotic cells was 
performed as described (23,  24).  To  discriminate T  and B  cell 
death, staining by anti-Thy-l.2-FITC or anti-B220-FITC were 
combined with EtBr staining. All analyses were carried out using 
FACScan|  (Becton  Dickinson &  Co.,  Mountain  View,  CA). 
Percentage of EtBr-positive cells in each population were defined 
as percentage of EtBr. For comparative purposes, data were nor- 
malized in some experiments as follows: 
% specific  death = 
(% EtBr in treated Bcl-2- cells -  % EtBr in treated Bcl-2 + cells) 
(% EtBr in untreated Bcl-2- cells -  % EtBr in untreated Bct-2 + cells). 
With any treatment used in this study, the percentage of EtBr 
in treated and untreated Bcl-2 + cells was comparable (difference 
was usually within 15%). 
Results 
Inhibition  of Apoptosis  in  Bd-2-  Mature  Lymphocytes  by 
Anti-CD3  Stimulation.  Thymocytes (80-90% immature T 
cells, 10-20% mature T  cells), spleen cells ('-'q0% mature T 
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Figure  1.  Spontaneous apoptosis in  in  vitro 
culture  and its inhibition  by anti-CD3  mAb. 
Cells isolated  from thymus (left), spleen (middle), 
and lymph nodes (nght) were cultured for 20 h 
in the  absence (black) or presence (hatched) of 
anti-CD3 mAb (145-2C11; I p.g/ml), followed 
by staining with hypotonic fluorescent solution 
(23), and the  percentage of hypodiploid cells 
was determined. The means of triplicated cul- 
ture with SDs are shown. 
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Fig'are 2.  Both T  and B lymphocytes undergo apop- 
tosis in vitro. Lymph node cells from Bcl-2 + (left) and 
Bcl-2-  (right) mice were placed  in  culture  for 20  h, 
then stained  with B220-FITC and EtBr.  Note the sig- 
nificant  increase  in EtBr  + cells, representing apoptotic 
cells,  in  not  only  the  B220-  fraction,  but  also  the 
B220 + fraction of the Bcl-2- lymph node cells. 
cells,  50% mature B  cells,  40% non-T, non-B cells),  and 
lymph  node  cells  (~60%  mature  T  cells,  35% mature  B 
cells) were prepared from Bcl-2  + and Bcl-2- animals in the 
same litter. Cells were placed in culture for 20 h  with or 
without  anti-CD3  mAb  (1  gtg/ml).  After  culture,  cells 
were stained by a hypotonic fluorescent solution contain- 
ing 50 Izg/ml propidium iodide (23), and the percentage of 
hypodiploid cells,  representing apoptotic cells, was assayed 
(Fig.  1). In thymocytes, apoptosis in Bcl-2- cells was mod- 
erately higher  than  in  Bcl-2  +  cells.  Since  >80%  of thy- 
mocytes do not (or barely) express Bcl-2 normally, the dif- 
ference between Bcl-2  +  and Bcl-2- probably result from 
apoptosls  of mature  thymocytes, which  normally express 
Bcl-2 (8, 9). In contrast, immature thymocytes express Bcl- 
x, which is a member of the bcl-2 gene family and may pre- 
vent apoptosis  of immature  thymocytes (25,  26).  Bcl-2- 
peripheral lymphocytes showed a significant increase in ap- 
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Figure 3.  Anti-CD3  stimulation inhibits the  spontaneous apoptosis of 
mature  T  and  B  cells. Lymph node  cells  were  placed  in  culture  and 
stained  in the combination with B220-FITC and EtBr as shown in Fig. 2. 
Percentage of specific death in T  cells (black bars) and B cells (hatched bars) 
was calculated  as described in Materials  and Methods. Cells were cultured 
with (CD3) or without (MED)  1 I~g/ml anti-CD3 mAb. Cyclosporin A 
was added at the concentration of 0.1  I~M (CSA+)  or 1 I~M (CSA++) 
with anti-CD3 mAb. CsA alone did not affect the viability  of lympho- 
cytes in the concentration used (data not shown)￿9  The means oftriphcated 
culture with SDs are shown￿9 
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optosis  (Fig.  1).  Of note,  the  increase  in  apoptosis  was 
more evident in lymph node cells than in spleen cells, sug- 
gesting that differences in cell populations may affect apop- 
tosis (as discussed below). 
The observed dramatic apoptosis does not appear to re- 
quire any specific induction or stimuli.  First,  we failed to 
block this apoptosis by addition of RU-486,  a potent in- 
hibitor of glucocorticoid receptors (data  not shown).  Sec- 
ond, we generated bcl-2 -/-  Ipr/lprrrfice to test for the require- 
ment of signaling  via  Fas  for the  induction  of apoptosis. 
Peripheral lymphocytes lacking both Bcl-2 and Fas showed 
the same high degree ofapoptosis as did those lacking Bcl-2 
only, while less apoptosis was observed in Bcl-2+/Fas  + and 
Bcl-2+/Fas -  control cells (data not shown). For simplicity, 
here  we  designate  this  accelerated apoptosis  observed in 
Bcl-2-  cells as  "spontaneous apoptosis." The spontaneous 
apoptosis in Bcl-2- mature lymphocytes could be inhibited 
by anti-CD3  treatment in the periphery, while anti-CD3 
treatment induced increased apoptosis among thymocytes 
(Fig.  1). 
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Figure 4.  Effect  of cytokines on  the spontaneous apoptosis in Bcl-2- 
lymphocytes￿9 Lymph node cells were cultured for 20 h in medium alone 
(MED) or with IL-lct, IL-2, IL-4, IL-7, and IFN-~t.  All cytokines were 
used at 100 U/ml. Staining was carried  out as in Fig. 2, and the percent- 
age  of specific  death  in  T  cells (black bars) and  B  cells  (hatched bars) is 
shown. The means of triplicated  culture with SDs are shown. 1201  T  Cell  1~ 
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Figure  5.  Synergistic inhibition of anti-CD?r-induced 
protection ofBcl-2- lymphocytes  by anti-IL-4 and anti- 
CD40L antibodies. Cultures were done as in Fig. 3, ex- 
cept for the  presence of anti-IL-4  (1  p,g/ml), anti- 
CD40L (+;  10  ~g/ml,  ++;  50 Ixg/ml), or both in 
some cases. Percentage of specific death in T cells (let)) 
and B cells (right) was depicted. The means of tripli- 
cated culture with SDs are shown, except for 50 Ixg/ml 
anti-CD40L treatment (in duplicate). 
Anti-CD3  Stimulation  Inhibits  both T  and B  Cell Apoptosis. 
To determine  which lineage  of cells  underwent  apoptosis, 
dual-color  FACS  |  analyses  with  FITC-labeled  antibodies 
and EtBr were  performed  (24).  As shown  in  Fig.  2,  both 
B220 +  and  B220-  lymph  node  cells  showed  significantly 
greater apoptosis in Bcl-2- cells  than in Bcl-2  + cells.  Since 
most lymph node cells consist ofT and B  cells,  B220- cells 
primarily represent  T  cells.  Consistent with  this,  the result 
of Thy-I-FITC/EtBr staining of lymph node cells  was re- 
ciprocal to that of  B220-FITC/EtBr (data not shown). The 
observed  T  cell  death  was  more  pronounced  than  B  cell 
death among Bcl-2- lymph node cells (Fig. 2).  Since T  cell 
content in the lymph node is much higher than that in the 
spleen,  this  may  explain  why  spontaneous  apoptosis  was 
more  evident  previously in Bcl-2- lymph  node  cells  than 
in spleen cells. 
Unexpectedly, anti-CD3 treatment inhibited the sponta- 
neous apoptosis, not only in Bcl-2- T  cells,  but also in Bcl- 
2  B  cells (Fig. 3).  This rescue effect of anti-CD3 stimula- 
tion was dependent on the coexistence ofT  and B  cells  (as 
shown in Fig.  7),  and was reversed by the addition  of cy- 
closporin  A  (CsA)  in  a  dose-dependent  manner  (Fig.  3). 
Antibody-induced inhibition  of the spontaneous  apoptosis 
appeared to be specific to anti-CD3: anti-CD2,  anti-CD4, 
anti-CD8, or anti-Thy-1 mAb did not affect the spontane- 
ous apoptosis (data not shown). These results eliminate the 
possibilities  that nonspecific  cross-linking of T  and B  cells 
inhibited  the  spontaneous  apoptosis,  or  that  signaling  via 
the Fc receptor is solely responsible for the inhibition  of B 
cell death.  Thus,  we hypothesized that certain molecule(s) 
on the T  cells,  either membrane-bound or secreted,  might 
be induced by anti-CD3,  and mediate  the inhibition  of B 
cell death. 
IL-4 Blocks Spontaneous  Apoptosis  in Bcl-2-  T  and B  Cells. 
Some ILs or cytokines can inhibit lymphocyte death under 
certain  conditions.  These include  IL-1  (27,  28),  IL-2 (28- 
31),  IL-4  (32-34),  and  IFN-~/  (35,  36).  To  test  whether 
these soluble factors may inhibit the spontaneous apoptosis 
due  to  the  lack  of Bcl-2,  recombinant  mouse  ILs  were 
added into  cultures  (Fig.  4).  We  failed to find any signifi- 
cant  inhibitory  effect  on  the  spontaneous  apoptosis  with 
IL-1 or IL-2. In contrast, IL-4 clearly inhibited both T  and 
B  cell apoptosis.  IL-7, which induces growth of mature  T 
cells  and early differentiation  of B  cell precursors,  remark- 
ably inhibited T  cell apoptosis.  Although IL-7 also affected 
B  cell  apoptosis,  the  degree  of inhibition  was less  promi- 
nent.  This suggests that the survival of T  cells  may not be 
sufficient for the avoidance of B  cell apoptosis.  In addition, 
IFN-y showed moderate inhibition  of T  and B  cell apop- 
tosis  (Fig.  4),  although  increased  concentrations  of IFN-2t 
could not further block the spontaneous apoptosis (data not 
shown).  It is possible  that a subpopulation of cells  was res- 
cued by IFN-y. 
CD40  and  IL-4 Are  Mediators  of the  Inhibition  of B  Cell 
Apoptosis by Anti-CD3-activated  T  Cells.  Some reports dem- 
onstrated that the stimulation of CD40 on B  cells  by stimu- 
latory  antibody  or  its  natural  ligand,  CD40L,  rescued  B 
cells  from apoptosis  (14,  15,  37-39).  CD40L is specifically 
expressed  on  activated  T  cells,  e.g.,  after  stimulation  by 
anti-CD3 mAb (21, 40). To address the possible requirement 
and role for CD40 and IL-4 in the suppression of spontane- 
ous apoptosis,  we performed  an  inhibition  experiment  by 
using blocking antibodies against CD40L and IL-4. Protec- 
tion of Bcl-2- T  cells from spontaneous apoptosis by anti- 
CD3  was  almost  unaffected  by  the  addition  of the  anti- 
CD40L and anti-IL-4 mAbs (Fig. 5). In contrast, anti-CD40L 
Figure 6.  Inhibition of spontaneous apoptosis in Bcl-2  TCR_-trans- 
genic lymphocytes by the specific peptide antigen. Lymph node  cells 
were isolated from Bcl-2- nontransgenic mice (Bd-2-) or Bcl-2- TCR 
transgenic mice (Bcl-2-/TCR-TG),  which are specific for cOVA (323- 
339) peptide. Cells were cultured for 20 h in medium alone (black bars), 
with 1 Ixg/mI anti-CD3 mAb (hatched bars), or with 5 ~M cOVA (323- 
339) peptide (shaded  bars). Percentage of specific death in T cells (left) and 
B cells (right) is shown. The means of triplicated culture with Slgs are 
shown. Note that specific inhibition of apoptosis with cOVA peptide was 
seen only in Bcl-2- TCR transgenic lymphocytes. 
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Figure 7.  Inhibition of spontaneous apoptosis in Bcl-2- lg transgenic B 
cells by antigen-specific T-B cell collaboration.  (/t)  Lymph  node cells 
were  cultured  in medium alone  (MED),  with  1 p~g/mJ cOVA  protein 
(cOVA pro),  1 p~M cOVA (323-339) peptide  (cOVA pep), or  1 ~g/ml 
anti-CD3 mAb (CD3), in the absence (black bars) or presence (hatched bars) 
ofTC1L transgenic T cells that are specific for cOVA (323-339) peptide. 
Because of the presence of T  cells from Bcl-2- or Bcl-2  Ig transgenic 
mice (Bcl-2 /Ig-TG) in the culture, anti-CD3 could suppress the apopto- 
sis of Bcl-2- B cells regardless of the presence of cOVA peptide-specific 
transgenic T cells. In contrast, cOVA peptide could inhibit  the B cell apop- 
tosis only in the presence of cOVA-specific transgenic T  cells. Addition 
ofcOVA protein did not affect B cell apoptosis significantly in short-term 
(24 h) cultures. (B) Inhibition of B cell apoptosis by cOVA protein takes 
place at a later stage. Purified splenic B cells were prepared as described in 
Materials and Methods and were cultured for 24 h (left) or 72 h (right) in 
the absence (black bars) or presence (hatched bars) ofcOVA-specific TCP, 
transgenic T cells. Cross-linked cOVA protein was added at a concentra- 
tion of 1 p~g/ml. In the 72-h culture,  100 U/ml [L-4 was added for the 
first 48 h and was then withdrawn by washing. In the 24-h culture,  no 
significant reduction of Bcl-2- B cell apoptosis was observed  in either 
Bcl-2- nontransgenic or Ig transgenic B cells, as described above. In con- 
wast, at 72 h, specific  inhibition was detected only in the presence of cOVA- 
specific B cells and cOVA-specific T cells with cOVA protein. 
Antigen-specific  T-B  Cell  Collaboration  Inhibits  Spontaneous 
Apoptosis.  To confirm the effect ofanti-CD3 stimulation on 
spontaneous  apoptosis  under  more  physiological  condi- 
tions, we have established a system that recapitulates an an- 
tigen-specific  collaboration  between  T  cells  and  B  cells. 
Mice  transgenic for TCR  and Ig specific  for  cOVA  were 
bred with  bcl-2 +/-  mice,  and  F1  mice  carrying the  [tans- 
genes and mutant alleles of bcl-2 were  intercrossed to  gen- 
erate  bd-2 -/-  transgenic  mice.  The  Bcl-2-  transgenic  T 
cells and B  cells showed the same dramatic apoptosis as did 
nontransgenic Bcl-2- cells (Figs. 6 and 7). Fig. 6 shows apop- 
tosis  in  lymph  node  cells  from  Bcl-2-  TCR  transgenic 
mice. Anti-CD3 treatment suppressed the spontaneous apop- 
tosis  of T  and B  cells from Bcl-2- nontransgenic mice,  as 
well as  those  from Bcl-2-  TCP,.  transgenic mice.  In con- 
trast, cOVA peptide inhibited the apoptosis only in the TC1L 
transgenic Bcl-2- T  and B  cells, but not in nontransgenic 
Bcl-2- T  and B  cells. Since B  cells in the culture were not 
antigen specific, specificity of Ig on the B  cells appeared ir- 
relevant to  the suppression of apoptosis when cOVA pep- 
tide  was  added.  This  suggests  that  the  antigen-presenting 
function of B  cells is primarily important in the inhibition 
of Bcl-2- T  and B  cells. Moreover,  this also eliminates the 
possibility that signaling via the Fc receptor on the B  cells is 
necessary for the inhibition ofapoptosis in B  cell apoptosis. 
Using cells from Bcl-2- Ig transgenic mice, we tested for 
the  inhibition  of  B  cell  apoptosis  with  cOVA  protein, 
cOVA peptide (323-339), or anti-CD3 in the presence and 
absence  of cOVA-specific  T  cells.  The  concentration  of 
cOVA  protein  was  carefully determined  to  maximize  Ig- 
dependent responses  and  to  minimize [g-independent pi- 
nocytosis of cOVA (20). As shown in Fig. 7  A, the sponta- 
neous apoptosis of B  cells from Bcl-2- nontransgenic mice 
and Bcl-2-  Ig transgenic mice was  inhibited by anti-CD3 
mAb significantly blocked the rescue orB  cell apoptosis by 
anti-CD3 (Fig. 5).  Anti-IL-4 synergized with anti-CD40L 
to inhibit up to 80% of the rescue, but showed only a slight 
effect  by  itself.  Yet,  the  inhibition never  reached  100%, 
suggesting  that  other  soluble  or  membrane-bound  mole- 
cules  may  further  contribute  to  the  suppression  of B  cell 
apoptosis. We conclude that the rescue ofBcl-2- B  cell apop- 
tosis  by  anti-CD3  stimulation  was  mediated  mainly 
through CD40 and IL-4. Bcl-2 appears to not be necessary 
for signaling via CD40 and IL-4 receptor on B  cells because 
the inhibition of apoptosis was observed in Bcl-2- cells. 
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Figure 8.  A model for the inhibition  of spontaneous apoptosis in Bcl-2- 
deficient T and B cells by antigen-specific T-B cell collaboration.  Bcl-2- 
deficient Ig transgenic B cells (Bd2-/Ig-TG B cell) capture the cOVA pro- 
tein (cOVApro) through  their Igs and process it to present small peptides 
(cO VApep) in the groove of variable domains of class II MHC molecules 
(I-A a) to Bcl-2-deficient  TCP, transgenic T cells (BcI2-/TCR-TG  Tcell). 
Engagement of the TCR by the peptide--MHC complex confers a signal 
to suppress T cell apoptosis, induces surface expression of CD40L, and re- 
leases ILs, including  IL-4. Consequently, signaling via CD40 and the IL-4 
receptor blocks the apoptosis in B cells in a Bcl-2  independent manner. regardless  of the presence ofcOVA-specific T cells because 
of the  presence  of nonspecific T  cells  in  the  culture.  In 
contrast, cOVA peptide could inhibit the apoptosis only in 
the presence of cOVA-specific T  cells  (Fig.  7 A).  How- 
ever,  cOVA  protein,  which  engages  the  transgenic  Ig, 
could not block the spontaneous apoptosis in the transgenic 
B  cells in a 24-h culture (Fig.  7, A  and B).  Furthermore, 
engagement of the Ig by anti-IgM antibody, which is be- 
lieved to cross-link Igs much more strongly than antigens 
do,  did  not  rescue  the  B  cells  from  apoptosis  (data  not 
shown). Thus, engagement of the Ig alone is unlikely to be 
a sufficient signal for the inhibition of  B cell apoptosis. 
We hypothesized that the processing of the cOVA pro- 
tein and presentation of the appropriate peptide to T  cells 
in the context of class II MHC may be necessary. To test 
this hypothesis, we performed long-term (72-h) culture to 
allow antigen-specific B cells to process the cOVA protein 
(Fig.  7  B).  IL-4 was  added in culture for the first 48 h  to 
maintain the viability of Bcl-2- cells,  and it was removed 
24  h  before the  end of culture. Without  cOVA protein, 
nontransgenic and Ig-transgenic Bcl-2- B  cells underwent 
a comparable degree ofapoptosis (data not shown). In con- 
trast,  the addition of cOVA protein suppressed the B  cell 
apoptosis only in the Ig transgenic Bcl-2- B  cells, but not 
in the nontransgenic Bcl-2- B cells (Fig. 7 B). This inhibi- 
tion ofapoptosis was dependent on the presence ofcOVA- 
specific helper T  cells.  This result, specifically observed in 
Ig-transgenic B  cells, minimizes the possibility that cOVA 
protein was  nonspecifically degraded to small  peptides by 
proteases  present  in  the  serum.  Instead,  it  is  likely  that 
transgenic  B  cells  effectively capture  the  cOVA  protein 
through the cOVA-specific Ig, and present the cOVA pep- 
tide to the cOVA-specific T  cells in the context of class II 
MHC  molecules  after proper  processing  of the  protein. 
This is consistent with the kinetics of antigen-dependent B 
cell activation observed in vitro (20). 
Hence, as depicted in Fig.  8, the inhibition of spontane- 
ous apoptosis appears to be dependent on the cognate in- 
teraction between T  and B  cells.  B  cells capture antigens 
through their Igs and process them to present small  pep- 
tides, complexed with class 1I MHC molecules, to T  cells. 
Activated T  cells then express CD40L and release ILs in- 
cluding IL-4. In turn, signaling via CD40 and the IL-4 re- 
ceptor blocks the apoptosis in B cells. 
Discussion 
The  Bcl-2  oncoprotein  functions  as  an  antiapoptotic 
molecule in many experimental systems  (3). The restricted 
expression of Bcl-2 to long-lived cells also implies the im- 
portance of Bcl-2 in the prevention of apoptosis  (6).  Not 
only the spatial  distribution  of Bcl-2  expression, but  also 
the developmental regulation of  Bcl-2 expression in certain 
lineages of cells reinforces the notion that Bcl-2 is an anti- 
apoptosis molecule. Bcl-2 is expressed at early and late stages 
of T  and B  lymphocyte development, but it is downreg- 
ulated  in  cells  undergoing  selective  processes,  including 
CD4+8 + thymocytes, IgM+D -  immature B cells, and ger- 
minal  center B  cells  (8-10,  4l).  Our data presented here 
demonstrate that lymphocytes lacking Bcl-2 expression die 
rapidly.  The biphasic  expression of Bcl-2 commonly ob- 
served in both T and B cell development may render T and 
B  cells  susceptible  to  apoptosis  during  specific  selection 
stages  and  protect  them  from  apoptosis  at  other  times. 
Thus, Bcl-2 appears to be a main regulator of susceptibility 
to apoptosis in T  and B  lymphocyte development. There 
may be a physiological rescue signal  from such apoptosis- 
sensitive Bcl-2- status.  The signaling we described in this 
paper may be responsible for the rescue. 
Recently, we and others have described the requirement 
for Bcl-2 in the maintenance  of the lymphoid system.  In 
Bcl-2- mice, the initial development of T  and B lympho- 
cytes was unexpectedly intact, but mature lymphocytes dis- 
appeared (16-18). The Bcl-2- mature lymphocytes under- 
went  dramatic  apoptosis  in  vivo  and  in  vitro.  Since  the 
reduction of the number oflymphocytes becomes apparent 
with the age of  Bcl-2-deficient mice, the changing level of 
glucocorticoid in the serum may account for the delayed 
onset of lymphoid abnormalities (42).  However, at least in 
vitro, Bcl-2- lymphocytes were still susceptible to apopto- 
sis in the presence of 1 tzM RU-486, a potent inhibitor of 
glucocorticoid receptors that clearly inhibited dexametha- 
sone-induced apoptosis in thymocytes in vitro (our unpub- 
lished observations). Therefore, the apoptosis  observed in 
vitro could not be explained by the presence of steroids in 
the FCS. Another possibility is that Bcl-2 might normally 
counter the signaling via Fas, a mediator of apoptosis. The 
absence of Bcl-2 may render the Fas-mediated signal  con- 
stitutive  and  result  in  apoptosis.  Fas  is  not  expressed  on 
most resting B  lymphocytes, however, and Bcl-2-Fas- B 
lymphocytes still showed drastic apoptosis.  Hence, the apop- 
tosis in Bcl-2- lymphocytes appears to take place without 
any inducing stimuli.  There is  some  evidence that Bcl-2 
functions in  an  antioxidant pathway,  and  the  antioxidant 
ability may be sufficient for the inhibition of apoptosis (43, 
44).  If this is the case, oxidative substances,  which are nor- 
really antagonized by Bcl-2, may be produced in the ma- 
ture lymphocytes. Lack of Bcl-2 might allow such oxida- 
tive substances to be accumulated,  resulting in cell death. 
However, we could not observe any significant effect of ei- 
ther N-acetyl-L-cysteine or ascorbic acid, which are potent 
antioxidative agents and effective in inhibition of apoptosis 
(43,  44), on the spontaneous apoptosis in Bcl-2- lympho- 
cytes (our unpublished observations). 
Unexpectedly, the apoptosis observed in Bcl-2- mature 
T  cells  was  much more evident than  that in Bcl-2- thy- 
mocytes, suggesting the presence of redundant molecule(s) 
in thymocytes. Bcl-xL, another member of the Bcl-2 fam- 
ily, is expressed in CD4+8 + thymocytes, but not in mature 
T  cells,  and protects them from apoptosis  (26).  Initial  re- 
ports failed to detect Bcl-xL expression in the human thy- 
mus, whereas it was demonstrated that Bcl-xS, which is a 
dominant negative molecule produced by alternative splic- 
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we detected much more Bcl-xL than Bcl-xS in the mouse 
thymus, and we have shown that Bcl-xL may be function- 
ally dominant because targeted disruption of bcl-x gene re- 
sulted  in  marked  increase  in  apoptosis  of CD4+8 §  thy- 
mocytes (26). The functional difference between Bcl-2 and 
Bcl-x has not been clear.  Since mature T  cells  (Bcl-2  high, 
Bcl-x  l~  have  a  much longer lifespan than  do  immature 
thymocytes (Bcl-2  l~  Bcl-x  high) (45, 46), Bcl-2 may have a 
stronger effect on the longevity oflymphocytes than Bcl-x. 
Alternatively, Bcl-xL may have a comparable ability to in- 
hibit apoptosis to Bcl-2, but the presence of Bcl-xS antago- 
nizes this Bcl-xL activity in CD4+8 + thymocytes. Conse- 
quently, in Bcl-2-deficient mice, an opposite phenomenon 
was observed: mature T  cells were more sensitive to apop- 
tosis  than to thymocytes. This could be explained by the 
presence of Bcl-x in thymocytes, but not in mature T  cells. 
Moreover, Bcl-x is reexpressed upon T  cell activation (25). 
Therefore, the inhibition of  spontaneous apoptosis in Bcl-2- 
lymphocytes by antigenic stimulation may result from up- 
regulation of Bcl-x. This possibility remains to be tested in 
Bcl-2/Bcl-x double-mutant mice. 
Our data suggest that T-B cell collaboration with spe- 
cific antigens inhibits the apoptosis in the absence of Bcl-2 
(Fig. 8): B cells capture the antigens by their Ig and present 
the digested peptide in the groove of variable domains of 
class II MHC molecules. T  cells specific for the peptide are 
activated by the peptide-MHC complex, and express CD40L 
on their surface as well as releasing ILs including IL-4. In 
turn, B cells escape from apoptosis with the help of T  cells, 
mainly through CD40 and IL-4, both of which have been 
shown to inhibit apoptosis in some experimental systems. 
CsA does not affect signaling via CD40 (47); thus, the inhi- 
bition  of anti-CD3-induced  rescue  of Bcl-2-  B  cells  by 
CsA may be the result of disruption of the T  cell activation 
process. CD40 and IL-4 show synergism in many cases, in- 
cluding B  cell proliferation (48),  secretion of IgE (49-51), 
and the induction of NF-AT (52).  It has been shown that 
signals via CD40 or IL-4 induce upregulation of Bcl-2 (11, 
33). Bcl-2 has  therefore been suspected as a key molecule 
in  the  pathway.  Bcl-2,  however, is  not necessary for the 
antiapoptotic activity of CD40 and IL-4 because signaling 
via  CD40  and  IL-4 inhibited B  cell apoptosis in  the  ab- 
sence of Bcl-2. This is consistent with the observation that 
Bcl-2 induction in germinal center B cells is a relatively late 
event compared to the suppression ofapoptosis (15). 
The  susceptibility of mature  lymphocytes to  apoptosis 
resulting from a lack of Bcl-2 is observed, not only in ex- 
perimental systems,  but also in normal animals. Upon im- 
munization, Bcl-2 is downregulated in germinal center B 
cells, which become susceptible to apoptosis (41).  Interest- 
ingly, it has recently been suggested that T  cells in the ger- 
minal centers are antigen-specific and selectively recruited 
into the germinal centers (53,  54).  Engagement of CD40 
on germinal center B  cells  that lack Bcl-2 expression, by 
CD40L on activated T  cells, suppresses  spontaneous apop- 
tosis  and upregulates Bcl-2 expression. In Bcl-2-deficient 
mice, circulating B cells showed high susceptibility to apop- 
tosis,  as seen in germinal center B  cells of wild-type mice, 
suggesting that the lack of Bcl-2 is the cause of the acceler- 
ated spontaneous apoptosis in germinal center B cells. More- 
over, spontaneous apoptosis in both germinal center B cells 
and  circulating B  cells  in  Bcl-2--deficient mice  could be 
suppressed by CD40 stimulation and IL-4. Given that both 
B  cells  are similar in characteristics of apoptosis,  our data 
suggest that germinal center B cells with high affinity to an- 
tigen after somatic hypermutation can be selectively rescued 
by activated T  cells in an antigen-specific, Bcl-2-indepen- 
dent  manner.  Bcl-2-independent  inhibition  of apoptosis 
during cognate T-B cell collaboration may be critically im- 
portant in the selection of germinal center B cells. 
Deregulated  expression  of Bcl-2  in  bcl-2-IgH  fusion 
minigene transgenic mice resulted in an expanded germinal 
center cell population, prolonged the lifespan of germinal 
center cells,  and augmented secondary immune responses 
(55,  56).  In  contrast, Bcl-2-deficient mice failed to form 
germinal centers efficiently after immunization, suggesting 
that  the  Bcl-2-independent inhibition is  not solely suffi- 
cient for such secondary responses as germinal center for- 
mation  (our  unpublished  observation).  Collectively,  the 
physiological function of  Bcl-2 in mature lymphocytes may 
be to protect lymphocytes from spontaneous apoptosis, and 
to promote their survival until they are activated by specific 
antigens. Thus, the lack of Bcl-2 may decrease the oppor- 
tunity for antigen-specific interaction, or it may reduce the 
ability to sustain  the interaction. The assays in vitro using 
transgenic T  and B  cells circumvent this problem because 
of the extremely high efficiency of antigen-specific cognate 
interaction (20).  Taken together, it is likely that both Bcl- 
2-dependent and -independent inhibition of apoptosis play 
important roles in lymphocyte development and differenti- 
ation. 
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